Conversion Ratio. The “Conversion Ratio” for each share of Series A Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series A Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.
Appears in 4 contracts
Samples: Agreement and Plan of Merger (Spyre Therapeutics, Inc.), Agreement and Plan of Merger (Aeglea BioTherapeutics, Inc.), Agreement and Plan of Merger (Aeglea BioTherapeutics, Inc.)
Conversion Ratio. The “Conversion Ratio” for each share of Series A Non-Non- Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series A Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Selecta Biosciences Inc)
Conversion Ratio. The “Conversion Ratio” for each share of Series A C Non-Voting Preferred Stock shall be 1,000 10,000 shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series A C Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1)Stock, subject to adjustment as provided herein.
Appears in 1 contract
Conversion Ratio. The “Conversion Ratio” for each share of Series A X Non-Voting Preferred Stock shall be 1,000 [1,000] shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series A X Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.
Appears in 1 contract
Conversion Ratio. The “Conversion Ratio” for each share of Series A Non-Voting Preferred Stock shall be 1,000 10 shares of Common Stock issuable upon the conversion (the “Conversion”) of each share of Series A Non-Voting Preferred Stock (corresponding to a ratio of 1,000:110:1), subject to adjustment as provided herein.
Appears in 1 contract
Samples: Agreement and Plan of Merger (Aprea Therapeutics, Inc.)
